Table 2.

Schedule of Assessments

Clinical Characteristics	Measurement	Validity/Reliability	Baseline	30/90/180 days
HF History and Diagnostics	Chart Abstraction Tool (based on risk36 and 37)	-	x	x
Comorbidities	Charlson Comorbidity Index38 (via record)	-	x
Hemodynamic Profile	Output, pressure, O2 extraction etc. (via record)	-	x	x
VAD Support	Flow, rotations, power, pulse index etc. (via record)	-		x
Other Potentially Influential Factors (Exploratory)
Socio-demographics	Socio-demographic Questionnaire	-	x
Perceived Control	Control Attitudes Scale-Revised39	α .73	x	x
Perceived Social Support	Perceived Social Support Scale40	α .84	x	x
Mild Cognitive Dysfunction	Montreal Cognitive Assessment41	100/83%‡	x	x
Physical Symptoms
Physical Symptoms	Heart Failure Somatic Perception Scale42	α .90¥	x	x
Pain Intensity/Interference	Brief Pain Inventory Short Form43	α .84–.94	x	x
Daytime Sleepiness	Epworth Sleepiness Scale44	α .83¥	x	x
Psychological Symptoms
Depression and Severity	Patient Health Questionnaire-945	α .86¥	x	x
Anxiety	Brief Symptom Inventory46 6 Anxiety Items	α .87¥	x	x
Hostility	Brief Symptom Inventory46 5 Hostility Items	α .83¥	x	x
Serum Biomarkers
Myocardial Stress	Amino terminal pro-B-type natriuretic peptide	11.75pg/mL*	x	x
Systemic Inflammation	Soluble tumor necrosis factor alpha receptor	0.77ng/mL*	x	x
Endothelial Dysfunction	Soluble endothelial-leukocyte adhesion molecule 1	0.009ng/mL*	x	x
Outcomes
HF Health-Related QOL	Kansas City Cardiomyopathy Questionnaire47	α .78–.95	x	x
Health-Related QOL	European Quality of Life 5 Dimensions48	θ	x	x
Clinical Events	Clinical Event Adjudication	-		x

^‡sensitivity/specificity for mild cognitive dysfunction with cut-off of 24;

^¥quantified using data from this same advanced HF population;⁵¹

^*minimal detection limits; θ mean of 0.78±0.18 in mild to 0.51±0.21 in severe HF.⁵⁰

Abbreviations: HF, heart failure; QOL, quality-of-life; VAD, ventricular assist device.